Myung Ah Lee

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · NEJM Evidence · 2022 · 986 citations

Placebo Monotherapy, Health Sciences, Gastrointestinal Oncology +15

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 891 citations · Full text

Urology, Surgical Oncology, Gastrointestinal Oncology +5

Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Eileen M. O’Reilly, Do‐Youn Oh, Neesha C. Dhani et al. · JAMA Oncology · 2019 · 722 citations · Full text

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study

Se Hoon Park, Heung-Moon Chang, Jun Suk Kim et al. · The Lancet Oncology · 2011 · 479 citations

Advanced Biliary-tract Cancer, Gastrointestinal Oncology, Medicine +7

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · Journal of Clinical Oncology · 2022 · 230 citations

Immunology, Pathology, Immunotherapeutics +18